Apontis Pharma (ETR:APPH) H1 2024 results
Key financial results
- Sales: €22.7 million (up 19% compared to the first half of 2023).
- Net profit: €702.8 thousand (after a loss of €3.52 million in the first half of 2023).
- Profit margin: 3.1% (after the net loss in H1 2023).
- Earnings per share: €0.084 (after a loss of €0.42 in the first half of 2023).
All figures shown in the graph above refer to the last 12 months (TTM)
Insights into Apontis Pharma’s earnings
An average sales growth of 18% per year is expected for the next three years. Growth of 3.7% is forecast for the pharmaceutical industry in Germany.
Performance of German pharmaceutical industry.
The company’s share price remained largely unchanged compared to the previous week.
Risk analysis
We don’t want to spoil the fun too much, but we also found 1 warning signal for Apontis Pharma that you need to consider.
New: Manage all your stock portfolios in one place
We have the the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of portfolios and see your total amount in one currency
• Be notified of new warning signals or risks by email or mobile phone
• Track the fair value of your stocks
Try a demo portfolio for free
Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.
This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.
